HomePress ReleasesMilliporeSigma Expands in Gillingham, UK, Boosts Distribution Capabilities

MilliporeSigma Expands in Gillingham, UK, Boosts Distribution Capabilities

News Release

  • Demonstrates MilliporeSigma’s commitment to the UK
  • Serves as the company’s primary distribution centre for the UK

Gillingham, United Kingdom, November 18, 2019 — MilliporeSigma, a leading science and technology company, today announced the completion of a £9 million expansion to its Gillingham distribution centre. With an added 5, 250 m², the new facility serves as MilliporeSigma’s primary distribution centre for the UK as part of the company’s global supply chain.

“This expansion increases our distribution capacity, reinforces our efforts in safety and allows us to operate more efficiently,” said Mark Jackson, Gillingham site director at MilliporeSigma. “It also helps to boost the local economy. With nearly a half million orders every year and more than 400,000 units in inventory at any given time, MilliporeSigma’s distribution centre is essential to the UK’s Life Science sector.”

The site supplies the pharmaceutical industry, biotechnology companies, research institutes and academic centres with biochemical and chemical reagents, laboratory supplies and testing services. All three of MilliporeSigma’s business sectors (Life Science, Healthcare and Performance Materials) are represented in the UK, where the company employs around 1,300 people at 12 locations.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. 

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.